1. ABSTRACT
Background Synaptic loss and neurite dystrophy are early events in Alzheimer’s Disease (AD). We aimed to characterise early synaptic microstructural changes in vivo.
Methods MRI neurite orientation dispersion and density imaging (NODDI) and diffusion tensor imaging (DTI) were used to image cortical microstructure in both sporadic, late onset, amyloid PET positive AD patients and healthy controls (total n = 28). We derived NODDI measures of grey matter extracellular free water (FISO), neurite density (NDI) and orientation dispersion (ODI), which provides an index of neurite branching and orientation, as well as more conventional DTI measures of fractional anisotropy (FA), mean/axial/radial diffusivity (MD, AD, RD, respectively). We also performed [11C]UCB-J PET, which provides a specific measure of the density of pre-synaptic vesicular protein SV2A. Both sets of measures were compared to regional brain volumes.
Results The AD patients showed expected relative decreases in regional brain volumes (range, -6 to - 23%) and regional [11C]UCB-J densities (range, -2 to -25%). Differences between AD and controls were greatest in the hippocampus. NODDI microstructural measures showed greater FISO (range, +26 to +44%) in AD, with little difference in NDI (range, -1 to +7%) and mild focal changes in ODI (range, -4 to +3%). Regionally greater FISO and lower [11C]UCB-J binding were correlated across grey matter in patients (most strongly in the caudate, r2 = 0.37, p = 0.001). FISO and DTI RD were strongly positively associated, particularly in the hippocampus (r2 = 0.98, p < 7.4 × 10−9). After 12-18 months we found a 5% increase in FISO in the temporal lobe, but little change across all ROIs in NDI and ODI. An exploratory analysis showed higher parietal lobe FISO was associated with lower language scores in people with AD.
Conclusions We interpreted the increased extracellular free water as a possible consequence of glial activation. The dynamic range of disease-associated differences and the feasibility of measuring FISO on commercially available imaging systems makes it a potential surrogate for pathology related to synapse loss that could be used to support early-stage evaluations of novel therapeutics for AD.
Competing Interest Statement
AVV and ALH declare that they have no competing interests. PMM acknowledges consultancy fees from Novartis, Bristol Myers Squibb, Celgene and Biogen He has received honoraria or speakers honoraria from Novartis, Biogen and Roche and has received research or educational funds from Biogen, Novartis, GlaxoSmithKline and Nodthera. CB, AM, GR, YL, MH, JP, RNG, EAR are employees of Invicro, a Konica Minolta Company. JBR serves as Editor to Brain; Chief Scientific Advisor to ARUK; and have consultancies with UCB, Asceneuron, Biogen, WAVE, SV Health, Astex unrelated to the current work; and have research grants from Janssen, Lilly, AstraZeneca. LM is an employee of Biogen. RC is an employee and shareholder of AbbVie, Inc. LC is an employee and shareholder of Pfizer, Inc. AJS is a full-time employee and shareholder of Takeda Pharmaceuticals, Ltd. HT is an employee of Hamamatsu Photonics. RH is a full-time employee and shareholder of Bristol Myers Squibb.
Funding Statement
Alzheimers Society, grant number 440, AS-CTF-18-006 (AVV), NIHR Biomedical Research Centre, Imperial College London (AVV, PMM), UK Dementia Research Institute (supported by the UKRI Medical Research Council, Alzheimers Society and Alzheimers Research UK) (PMM), NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) (JBR), Medical Research Council (SUAG/051 G101400; MR/L023784/2; MR/N029941/1) (JBR)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants provided written informed consent. Ethical approval for this study was provided by the NHS London - Brighton & Sussex Research Ethics Committee (REC 18/LO/0179) for AD patients and East of England Cambridge Central & South Research Ethics Committee for controls. Radiation safety was approved by the Administration of Radioactive Substances Advisory Committee (ARSAC R92), London. Local site approval was provided by Imperial College London Joint Research Office.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Author email addresses:
Ashwin V Venkataraman a.venkataraman{at}imperial.ac.uk
Courtney Bishop Courtney.Bishop{at}invicro.co.uk
Ayla Mansur Ayla.Mansur{at}invicro.co.uk
Gaia Rizzo Gaia.Rizzo{at}invicro.co.uk
Yvonne Lewis yvonne.lewis1{at}invicro.co.uk
Ece Kocagoncu ek390{at}cam.ac.uk
Anne Lingford-Hughes anne.lingford-hughes{at}imperial.ac.uk
Mickael Huiban Mickael.Huiban{at}invicro.co.uk
Jan Passchier Jan.Passchier{at}invicro.co.uk
James B Rowe james.rowe{at}mrc-cbu.cam.ac.uk
Hideo Tsukada tsukada0412{at}nifty.com
David J. Brooks david.brooks{at}newcastle.ac.uk
Laurent Martarello laurent.martarello{at}biogen.com
Robert A. Comley robert.comley{at}abbvie.com
Laigao Chen laigao.chen{at}pfizer.com
Richard Hargreaves Richard.Hargreaves{at}bms.com
Adam J. Schwarz Adam.Schwarz{at}takeda.com
Roger N. Gunn Roger.Gunn{at}invicro.co.uk
Eugenii A. Rabiner Ilan.Rabiner{at}invicro.co.uk
Paul M Matthews p.matthews{at}imperial.ac.uk
Data Availability
Non-identifible data produced in the present study are available upon reasonable request to the authors
List of abbreviations
- [11C]
- 11-Carbon
- [18F]
- 18-Fluorine
- 1TC
- One-Tissue Compartment
- 2TC
- Two-Tissue Compartment
- ACE III
- Addenbrooke’s Cognitive Examination III
- AD
- Alzheimer’s Disease
- AD
- Axial Diffusivity
- Aβ
- Amyloid-β
- CN
- Cognitively Normal
- CS
- Centrum semiovale
- DTI
- Diffusion tensor imaging
- DVR
- Distribution volume ratio
- ER
- Endoplasmic Reticulum
- ETC
- Electron Transport Chain
- FA
- Fractional anisotropy
- FISO
- Fraction of isotropic
- GM
- Grey matter
- MBq
- Megabecquerel
- MCI
- Mild cognitive impairment
- MD
- Mean diffusivity
- MMSE
- Mini mental state examination
- MNI
- Montreal Neurological Institute
- MRI
- Magnetic Resonance Imaging
- ms
- Millisecond
- mSv
- Millisievert
- NART
- National Adult Reading Test
- NDI
- Neurite Density Index
- NIA-AA
- National Institute on Aging and Alzheimer’s Association
- NODDI
- Neurite Orientation Density and Dispersion Imaging
- ODI
- Orientation dispersion index
- PET
- Positron Emission Tomography
- PVC
- Partial Volume Correction
- RD
- Radial Diffusivity
- ROI
- Region of Interest
- SPM12
- Statistical Parametric Mapping version 12
- SUVr
- Standardised Uptake Value ratio
- SV2A
- Synaptic Vesicle Protein 2A
- UCB-J
- ((R)-1-((3-((11)C-methyl-(11)C)pyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl) pyrrolidin-2-one)
- WM
- White matter